Trade-margin cap of 30% extended to non-scheduled cancer medicines
Next story · 8 OctPre-COP31 in Fiji: India seeks “flexibility, pragmatism and mutual respect” and scaled-up climate finance
The government has approved a cap on trade margins for non-scheduled anti-cancer medicines at 30% of MRP. It expects prices to fall by up to 70% and patients to save about ₹2,500 crore a year. NPPA found average mark-ups of about 170% on such drugs. A 2019 cap on 42 cancer drugs saved ₹984 crore a year.
- Decision
- 8 Oct 2026
- Cap
- Trade margin ≤ 30%
- Covers
- Non-scheduled cancer drugs
- Saving
- ₹2,500 cr a year
Cancer drug trade margin cap: what happened?
Scheduled (essential) cancer drugs already have ceiling prices. The rest, the “non-scheduled” ones, did not, and their price could rise many times between factory and patient. This cap targets that gap.
- Government approved capping trade margins on non-scheduled anti-cancer drugs at 30% of MRP; expected to cut prices by up to 70% and save patients ₹2,500 crore a year [PIB].
- A DGHS expert committee will finalise the list; NPPA will notify [PIB].
How are drug prices controlled in India?
- Scheduled drugs (from the National List of Essential Medicines) have ceiling prices fixed by NPPA under the Drugs (Prices Control) Order, 2013.
- Non-scheduled drugs are not ceiling-priced; makers can raise MRP by up to 10% a year.
- Paragraph 19 of DPCO 2013 lets the government act in extraordinary circumstances in public interest. The 2019 trade margin cap used this power.
Who does what in this decision?
Steps announced by PIB
- Expert committee under DGHS finalises the list of medicines
- NPPA decides and issues the notification
- Margins capped at 30% of MRP
- Makers must keep current production levels
How does 2026 compare with 2019?
| Item | 2019 cap | 2026 cap |
|---|---|---|
| Drugs covered | 42 selected non-scheduled drugs | all non-scheduled anti-cancer drugs (list by DGHS committee) |
| Price effect | MRP down up to 91% | prices down up to 70% (expected) |
| Annual saving | ₹984 crore (526 brands) | ₹2,500 crore (expected) |
Why does Cancer drug trade margin cap matter?
| Angle | What to note |
|---|---|
| Health | Lowers out-of-pocket spending on a costly disease; cancer affects about 60 per lakh people (PIB). |
| Economy | Curbs profiteering in the supply chain without fixing manufacturer prices. |
| Federal | States like Maharashtra, Rajasthan and Karnataka had raised the issue. |
What are the challenges in Cancer drug trade margin cap?
- Shortages if sellers stop stocking low-margin drugs; hence the production-level condition.
- Monitoring MRPs across retail, hospital and online pharmacies is hard.
What should be done next on Cancer drug trade margin cap?
- Quick notification of the drug list and online price display.
- Track availability alongside price.
What can Prelims ask on Cancer drug trade margin cap?
- NPPA fixes ceiling prices under DPCO 2013.
- Paragraph 19 DPCO: extraordinary powers in public interest.
- 30% trade margin cap on non-scheduled cancer drugs (2026).
How to write about Cancer drug trade margin cap in Mains
Practice question (10 marks, 150 words): High out-of-pocket health spending in India is partly a problem of drug pricing. Discuss with reference to trade margin rationalisation for cancer medicines.
- Intro: 30% cap, ₹2,500 crore.
- Problem: 170% mark-up.
- Tools: DPCO, NPPA, para 19, 2019 example.
- Risks: supply, enforcement.
- Conclusion: pricing plus access.
Image: https://commons.wikimedia.org/wiki/File:Chemotherapy_vials.jpg
How to use this in Mains
If asked: Is trade-margin rationalisation an effective way to make medicines affordable? (GS-II)
Quote: “Government approved capping trade margins on non-scheduled anti-cancer drugs at 30% of MRP; expected to cut prices by up to 70% and save patients ₹2,500 crore a year [PIB].”
Use it: Strong evidence in the body; note it curbs supply-chain markups without touching manufacturer prices.
Exam angle
Prelims: NPPA, DPCO. · Mains GS-II: health; GS-III: pharma regulation.
Practice MCQs
Original practice questions (not PYQs).
The power used in 2019 to cap trade margins on 42 cancer drugs came from
Answer (b) & explanation
PIB, 8 Oct 2026.
Ceiling prices of scheduled medicines in India are fixed by
Answer (b) & explanation
NPPA fixes ceiling prices under DPCO 2013.
Questions students ask about this
What is the new trade margin cap on cancer drugs?
Margins on non-scheduled anti-cancer medicines will be limited to 30% of MRP.
How much will patients save?
About ₹2,500 crore a year, with prices expected to fall by up to 70%.
Which body issues the notification?
The National Pharmaceutical Pricing Authority (NPPA), after a DGHS expert committee finalises the list.
Keep studying
Go deeper
Official source: PIB, Department of Pharmaceuticals: Government expands cancer medicine price controls, 8 Oct 2026
facts from cited sources only; faculty review pending